Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

COMPLETED

Identifier: CI-TRIAL-00077688
Entity page: /trial/NCT02348216 ↗
Edges: 19

Neighbours: 3 cancers15 drugs
Drawn: 18 of 18 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma condition of …CONDITION_OFderived4 of 4
← condition of	Diffuse Large B-Cell Lymphoma registry condition “Refractory Diffuse Large B Cell Lymphoma (DLBCL)” mapped CURATED_BROADER	—	—	Diffuse Large B-Cell Lymphoma	1	Observed	clinicaltrials	graph →
← condition of	Diffuse Large B-Cell Lymphoma registry condition “Relapsed Diffuse Large B-Cell Lymphoma” mapped CURATED_BROADER

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma intervention of …INTERVENTION_OFderived15 of 15
← intervention of	Axicabtagene Ciloleucelgene therapy registry intervention “Axicabtagene Ciloleucel” (BIOLOGICAL) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Bendamustinesmall molecule registry intervention “Bendamustine” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Carboplatinsmall molecule registry intervention “Carboplatin” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Cisplatinsmall molecule registry intervention “Cisplatin” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Cyclophosphamidesmall molecule registry intervention “Cyclophosphamide” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Dexamethasonesmall molecule registry intervention “Dexamethasone” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Doxorubicinsmall molecule registry intervention “Doxorubicin” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Etoposidesmall molecule registry intervention “Etoposide” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Fludarabinesmall molecule registry intervention “Fludarabine” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Gemcitabinesmall molecule registry intervention “Gemcitabine” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Ifosfamidesmall molecule registry intervention “Ifosfamide” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Oxaliplatinsmall molecule registry intervention “Oxaliplatin” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Prednisonesmall molecule registry intervention “Prednisone” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Rituximabmonoclonal antibody registry intervention “Rituximab” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Vincristinesmall molecule registry intervention “Vincristine” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma intervention of …INTERVENTION_OFderived15 of 15

← intervention of

Axicabtagene Ciloleucelgene therapy

registry intervention “Axicabtagene Ciloleucel” (BIOLOGICAL) mapped ALIAS

—

not mapped

Observed

Radial view

Every edge, grouped by relationship

Paths